PCR-Based Molecular Platform to Enable Drastically Faster Bacterial Infection Diagnosis
|
By LabMedica International staff writers Posted on 08 Jun 2023 |
|
A new novel PCR-based molecular platform provides a significant advancement in diagnosing bacterial infections by offering an alternative to traditional culture methods and outperforming newer methods such as sequencing on the time and cost front, while also matching the scope of other PCR tests.
Inbiome’s (Amsterdam, the Netherlands) Molecular Culture technique significantly speeds up and improves the precision of bacterial diagnostics compared to traditional culture. This revolutionary diagnostic technique has the capability to identify the vast majority of bacterial species through a single test. It is particularly tailored to deliver accurate results from invasively collected samples, such as cerebrospinal fluid, pus, and joint aspirates. Unlike culture or traditional PCR-based methods, Molecular Culture is not selective, which means medical professionals don't need to decide in advance which bacteria to search for. Since it is based on DNA detection, it can easily identify or detect bacteria that are unknown, uncultivable or have been treated with antibiotics.
Compared to conventional tests, Molecular Culture is more sensitive and precise. It accurately diagnoses almost double the number of positive samples, significantly reducing the prevalence of false negatives often associated with traditional testing. This leads directly to more informed treatment decisions, consequently improving patient outcomes. Moreover, the diagnostic process is quick, efficient, and simple. It delivers reliable and actionable results within four hours without the need for specialized equipment or bioinformatics pipelines. This means patients recover more quickly, complications are minimized, and the duration of hospital stays is substantially reduced. Currently, Molecular Culture is being utilized in several hospitals in the Netherlands, demonstrating exceptional results.
Related Links:
inbiome
Latest Molecular Diagnostics News
- Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
- HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
- Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
- Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
- Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
- Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
- Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
- AI Reveals Immune Response Biomarkers Linked to Ebola Survival
- Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
- WHO Adds First Bundibugyo Ebola Molecular Test to Emergency Use Listing
- Blood Test Helps Guide Post-Surgical Treatment in Metastatic Colorectal Cancer
- Study Supports Earlier Genetic Testing for Hereditary Breast and Ovarian Cancer
- Noninvasive Biomarkers Advance Colorectal Cancer Risk Assessment
- Rapid Brush Biopsy Test Detects Oral Cancer in One Hour
- AI-Driven Blood Test Enhances Early Detection of Multiple Cancers
- Interpretable AI Tool Improves Prediction of Immunotherapy Response
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Pathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more
